Oral · GLP-1 agonist
Aleniglipron / GSBR-1290
9 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
9
Active
5
Recruiting
0
Completed
3
Sites
207
Countries
1
Endpoints
121
Composite endpoints
8
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
2
Phase 1/2
1
Phase 2
4
Phase 3
2
Trials by status
Not yet recruiting
2
Active, not recruiting
3
Completed
3
Unknown
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
59
Weight & body composition
44
Cardiometabolic biomarkers
8
Glycemic / diabetes
6
Patient-reported / QoL
4
Most-measured metrics
Top 20 metrics across this asset's endpoints
Treatment-emergent AEs (any)Safety/PK
6
AUC₀–∞Safety/PK
6
CmaxSafety/PK
6
TmaxSafety/PK
6
Body weight, % changeWeight
5
Body weight, absolute change (kg)Weight
5
Waist circumference, changeWeight
4
Serious AEs (any)Safety/PK
4
Plasma concentration (steady state)Safety/PK
3
Half-lifeSafety/PK
3
≥5% weight-loss respondersWeight
3
≥10% weight-loss respondersWeight
3
≥15% weight-loss respondersWeight
3
BMI, changeWeight
2
HbA1c, changeGlycemic
1
Fasting glucose, changeGlycemic
1
Total fat massWeight
1
Visceral fat, changeWeight
1
Lean massWeight
1
SF-36 totalPRO/QoL
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
9 of 9